Anti-VEGF treatments are currently used for improving vision among patients with age-related macular degeneration, diabetic maculopathy and macular oedema, all of which are conditions likely to be affecting vision trajectories in the ELSA population. This evidence concerns the gene VEGFA and diabetic maculopathy.